Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo
作者:Shuyi Li、Chan Li、Shubin Jin、Juan Liu、Xiangdong Xue、Ahmed Shaker Eltahan、Jiadong Sun、Jingjie Tan、Jinchen Dong、Xing-Jie Liang
DOI:10.1016/j.biomaterials.2017.08.021
日期:2017.11
efficacy of these drugs is severely limited by cisplatin resistance, and this can lead to the failure of chemotherapy. One of cisplatin resistance mechanisms is associated with overexpression of glutathione S-transferases (GSTs), which would accelerate the deactivation of cisplatin and decrease its antitumor efficiency. Nanoscale micelles encapsulating ethacraplatin, a conjugate of cisplatin and ethacrynic
铂基DNA加成剂在临床上广泛用于癌症化学疗法。但是,这些药物的抗肿瘤功效受到顺铂耐药性的严重限制,这可能导致化疗失败。顺铂耐药机制之一与谷胱甘肽S-转移酶(GST)的过度表达有关,这会加速顺铂的失活并降低其抗肿瘤效率。纳米囊团包裹了依他克拉铂,一种顺铂和乙炔酸(一种有效的GSTs抑制剂)的结合物,可以通过抑制GST的活性和绕开顺铂的失活来增强癌细胞中活性顺铂的积累。体外和体内结果提供了有力的证据,表明GSTs抑制剂修饰的顺铂前药与纳米颗粒包封相结合有助于铂的高效积累,显着增强了对顺铂耐药性癌症的抗肿瘤功效,并降低了系统毒性。据信,这些装载有依他克拉铂的胶束具有克服癌症对顺铂的耐药性的能力,并且将在不久的将来改善化学疗法对顺铂耐药的癌症的前景。